- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00669214
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp (SCALP)
May 12, 2017 updated by: Genentech, Inc.
A Phase IV Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
This was a Phase IV randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of subcutaneous efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque psoriasis with involvement of the scalp who had no previous exposure to efalizumab.
The study consisted of a screening period, a double-blind treatment period, an open-label treatment period, and an observation/follow-up period.
The study enrolled 100 patients.
11 patients were excluded from all analyses because of data issues.
Study Overview
Detailed Description
- Baselines for Raptiva group and placebo group at Day 84 are the same. The baseline is Day 0.
- Baselines for Raptiva group and placebo group at Day 168 are different. The baseline for Raptiva group at Day 168 is Day 0, but the baseline for Placebo group at Day 168 is Day 84
Study Type
Interventional
Enrollment (Actual)
89
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provide written informed consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) documents
- Be aged 18 years or older
- Have chronic (6 months or greater) moderate to severe plaque psoriasis with involvement of the scalp
- Have a whole body Physician's Global Assessment (PGA) rating of moderate (3) or severe (4) for psoriasis
- Have a scalp surface area affected by plaque psoriasis of 30% or more, assessed using Psoriasis Scalp Severity Index (PSSI)
- Have at least one of three clinical signs involving the scalp (erythema, induration, and desquamation) be rated as at least moderate (2) with the other two rated as at least slight (1) using PSSI
- Be a candidate for systemic therapy in the opinion of the investigator
- Be naive to efalizumab treatment
- For women of childbearing potential, must be willing to use a method of contraception acceptable to the investigator to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study and for 6 weeks after the last dose of efalizumab
Exclusion Criteria:
- Have had previous exposure to efalizumab or a history of hypersensitivity to any of its components
- Are using any excluded therapy
- Have a history of drug or alcohol abuse in the past five years
- Have a history in the past 5 years of a serious infection or currently have an ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial infection
- Have any history of opportunistic infections (e.g., systemic fungal infections, parasites)
- Are seropositive for hepatitis B antigen, hepatitis C antibody, or human immunodeficiency virus (HIV)
- Have a history of active tuberculosis or are currently undergoing treatment for tuberculosis, including latent tuberculosis with isoniazid
- Have the presence or history of malignancy within the past 5 years, including lymphoproliferative disorders
- Are pregnant or breastfeeding
- Have a diagnosis of hepatic cirrhosis, regardless of cause or severity
- Have a history in the last 5 years of thrombocytopenia
- Have a history in the last 5 years of hemolytic anemia or any other clinically significant anemia
- Have been exposed to any experimental and/or unapproved drugs or treatments within 30 days or 5 half-lives, whichever is longer, before the screening visit
- Have been vaccinated with a live virus or live bacteria within the 14 days before the first dose of efalizumab
- Have any medical condition that, in the judgment of the investigator, would jeopardize the patient's safety following exposure to study drug (efalizumab or placebo equivalent) or would significantly interfere with the patient's ability to comply with the provisions of this protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7.
After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
|
Experimental: Efalizumab
|
All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7.
After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients Who Achieved a ≥ 75% Decrease in Psoriasis Scalp Severity Index (PSSI) Score at 12 Weeks
Time Frame: Week 12
|
Proportion of patients who achieved a ≥ 75% decrease in PSSI score at 12 weeks (Day 84) relative to baseline.
The PSSI assessed: 1) extent of scalp psoriasis (i.e., percentage of area involved), which was scored from 1 to 6, where 1 = <10% and 6 = 90-100%); and 2) clinical signs (erythema, induration, and desquamation), which were scored from 0 to 4, where 0 = Absent and 4 = Severest possible).
The sum of the separate scores for erythema, induration, and desquamation was multiplied by the score for the involved area.
The PSSI score range was therefore 0-72.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients Who Achieved a ≥ 75% Decrease in PSSI Score at 24 Weeks
Time Frame: Week 24
|
Proportion of patients who achieved a ≥ 75% decrease in PSSI score at 24 weeks (Day 168) relative to baseline.
The PSSI assessed: 1) extent of scalp psoriasis (i.e., percentage of area involved), which was scored from 1 to 6, where 1 = <10% and 6 = 90-100%); and 2) clinical signs (erythema, induration, and desquamation), which were scored from 0 to 4, where 0 = Absent and 4 = Severest possible).
The sum of the separate scores for erythema, induration, and desquamation was multiplied by the score for the involved area.
The PSSI score range was therefore 0-72.
|
Week 24
|
Proportion of Patients Who Achieved a ≥ 50% Decrease in PSSI Score at 12 Weeks
Time Frame: Week 12
|
Proportion of patients who achieved a ≥ 50% decrease in PSSI score at 12 weeks (Day 84) relative to baseline.
The PSSI assessed: 1) extent of scalp psoriasis (i.e., percentage of area involved), which was scored from 1 to 6, where 1 = <10% and 6 = 90-100%); and 2) clinical signs (erythema, induration, and desquamation), which were scored from 0 to 4, where 0 = Absent and 4 = Severest possible).
The sum of the separate scores for erythema, induration, and desquamation was multiplied by the score for the involved area.
The PSSI score range was therefore 0-72.
|
Week 12
|
Proportion of Patients Who Achieved a ≥ 50% Decrease in PSSI Score at 24 Weeks
Time Frame: Week 24
|
Proportion of patients who achieved a ≥ 50% decrease in PSSI score at 24 weeks (Day 168) relative to baseline.
The PSSI assessed: 1) extent of scalp psoriasis (i.e., percentage of area involved), which was scored from 1 to 6, where 1 = <10% and 6 = 90-100%); and 2) clinical signs (erythema, induration, and desquamation), which were scored from 0 to 4, where 0 = Absent and 4 = Severest possible).
The sum of the separate scores for erythema, induration, and desquamation was multiplied by the score for the involved area.
The PSSI score range was therefore 0-72.
|
Week 24
|
Proportion of Patients Who Achieved a Whole Body (Including Scalp) Physician's Global Assessment (PGA) Rating of Clear (0), Almost Clear (1), or Mild (2) at 12 Weeks
Time Frame: Week 12
|
Proportion of patients who achieved a whole body (including scalp) PGA rating of 0, 1, or 2 at 12 weeks (Day 84) Physician's Global Assessment (PGA) scale: 0: Clear. No signs of plaque psoriasis.
|
Week 12
|
Proportion of Patients Who Achieved a Whole Body (Including Scalp) PGA Rating of Clear (0), Almost Clear (1), or Mild (2) at 24 Weeks
Time Frame: Week 24
|
Proportion of patients who achieved a whole body (including scalp) PGA rating of 0, 1, or 2 at 24 weeks (Day 168) For details on the PGA scale, refer to the Secondary Outcome Measure Description for 12 weeks.
|
Week 24
|
Mean Change in Scalpdex Score at 12 Weeks
Time Frame: The two time points for Mean Change in Scalpdex Score at 12 Weeks are Day 0 and Day 84
|
Mean change in Scalpdex score at 12 weeks (Day 84) relative to baseline.
The Scalpdex point scoring scale ranges from 1=NEVER, 2='RARELY', 3='SOMETIMES', 4='OFTEN' and 5='ALL THE TIME'.
|
The two time points for Mean Change in Scalpdex Score at 12 Weeks are Day 0 and Day 84
|
Mean Change in Scalpdex Score at 24 Weeks
Time Frame: Week 24
|
Mean change in Scalpdex score at 24 weeks (Day 168) relative to baseline.
The Scalpdex point scoring scale ranges from 1=NEVER, 2='RARELY', 3='SOMETIMES', 4='OFTEN' and 5='ALL THE TIME'.
|
Week 24
|
Mean Change in a Visual Analog Scale (VAS) of Scalp Itch at 12 Weeks
Time Frame: Week 12
|
Mean change in VAS of patient-reported scalp itch at 12 weeks (Day 84) relative to baseline.
The Visual Analog Scale (VAS) of patient-reported scalp itch measured the severity of a patient's scalp itch on a scale of 0 to 10, where 0 was "no itching," 5 was "moderate itching," and 10 was "severe itching."
|
Week 12
|
Mean Change in VAS of Patient-reported Scalp Itch at 24 Weeks
Time Frame: Week 24
|
Mean change in VAS of patient-reported scalp itch at 24 weeks (Day 168) relative to baseline.
The Visual Analog Scale (VAS) of patient-reported scalp itch measured the severity of a patient's scalp itch on a scale of 0 to 10, where 0 was "no itching," 5 was "moderate itching," and 10 was "severe itching."
|
Week 24
|
Mean Change in Percentage of Whole Body (Including Scalp) Body Surface Area (BSA) Affected by Psoriasis at 12 Weeks
Time Frame: Week 12
|
Mean change in percentage of whole body (including scalp) BSA affected by psoriasis at 12 weeks (Day 84) relative to baseline.
BSA was assessed by percentage of sites affected per body segment (head, trunk, and limbs).
Investigators were instructed to use the "rule of palm" to estimate lesional skin BSA (1% BSA = palm to first interphalangeal joint).
|
Week 12
|
Mean Change in Percentage of Whole Body (Including Scalp) BSA Affected by Psoriasis at 24 Weeks
Time Frame: Week 24
|
Mean change in percentage of whole body (including scalp) BSA affected by psoriasis at 24 weeks (Day 168) relative to baseline.
BSA was assessed by percentage of sites affected per body segment (head, trunk, and limbs).
Investigators were instructed to use the "rule of palm" to estimate lesional skin BSA (1% BSA = palm to first interphalangeal joint).
|
Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2008
Primary Completion (Actual)
January 1, 2009
Study Completion (Actual)
January 1, 2009
Study Registration Dates
First Submitted
April 28, 2008
First Submitted That Met QC Criteria
April 28, 2008
First Posted (Estimate)
April 30, 2008
Study Record Updates
Last Update Posted (Actual)
June 6, 2017
Last Update Submitted That Met QC Criteria
May 12, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACD4412n
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on efalizumab
-
NYU Langone HealthGenentech, Inc.CompletedHidradenitis SuppurativaUnited States
-
Oregon Health and Science UniversityCompletedDermatitis, Atopic
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Merck KGaA, Darmstadt, GermanyCompletedModerate to Severe PsoriasisSwitzerland
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Norwegian University of Science and TechnologyTerminatedPlaque PsoriasisNorway
-
Washington University School of MedicineGenentech, Inc.CompletedLichen Planus, OralUnited States